JP2016519763A - プロテオームｉｐｆマーカー - Google Patents

プロテオームｉｐｆマーカー Download PDF

Info

Publication number
JP2016519763A
JP2016519763A JP2016503081A JP2016503081A JP2016519763A JP 2016519763 A JP2016519763 A JP 2016519763A JP 2016503081 A JP2016503081 A JP 2016503081A JP 2016503081 A JP2016503081 A JP 2016503081A JP 2016519763 A JP2016519763 A JP 2016519763A
Authority
JP
Japan
Prior art keywords
lung disease
fibrotic lung
protein
expression level
axis shows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519763A5 (enExample
Inventor
コッセン，カール
チン，シャオリ
リム，シャーリーン・アール
ザイベルト，スコット・ディー
ルールムント，ドナルド
Original Assignee
インターミューン， インコーポレイテッド
インターミューン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターミューン， インコーポレイテッド, インターミューン， インコーポレイテッド filed Critical インターミューン， インコーポレイテッド
Publication of JP2016519763A publication Critical patent/JP2016519763A/ja
Publication of JP2016519763A5 publication Critical patent/JP2016519763A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
JP2016503081A 2013-03-15 2014-03-14 プロテオームｉｐｆマーカー Pending JP2016519763A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361801290P 2013-03-15 2013-03-15
US201361801476P 2013-03-15 2013-03-15
US61/801,476 2013-03-15
US61/801,290 2013-03-15
US201361874947P 2013-09-06 2013-09-06
US61/874,947 2013-09-06
PCT/US2014/029392 WO2014144821A1 (en) 2013-03-15 2014-03-14 Proteomic ipf markers

Publications (2)

Publication Number Publication Date
JP2016519763A true JP2016519763A (ja) 2016-07-07
JP2016519763A5 JP2016519763A5 (enExample) 2017-04-13

Family

ID=51537804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503081A Pending JP2016519763A (ja) 2013-03-15 2014-03-14 プロテオームｉｐｆマーカー

Country Status (11)

Country Link
US (1) US9726677B2 (enExample)
EP (1) EP2972392A4 (enExample)
JP (1) JP2016519763A (enExample)
KR (1) KR20150130408A (enExample)
CN (1) CN105122068A (enExample)
BR (1) BR112015023699A2 (enExample)
CA (1) CA2901384A1 (enExample)
HK (1) HK1219533A1 (enExample)
MX (1) MX2015012778A (enExample)
RU (1) RU2015144149A (enExample)
WO (1) WO2014144821A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020090683A1 (ja) * 2018-10-29 2020-05-07 国立大学法人東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
JPWO2021024856A1 (enExample) * 2019-08-02 2021-02-11

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
CA2901384A1 (en) 2013-03-15 2014-09-18 Intermune, Inc. Proteomic ipf markers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension
WO2018191751A1 (en) * 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis
CN107677835B (zh) * 2017-09-26 2019-08-09 上海市肺科医院 一种ae-ipf的蛋白标记物及其应用
EP3837550A1 (en) * 2018-08-17 2021-06-23 Roche Diagnostics GmbH Circulating bmp10 (bone morphogenic protein 10) in the assessment of atrial fibrillation
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN110333358A (zh) * 2019-06-24 2019-10-15 浙江大学 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法
WO2021181368A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
US20230146286A1 (en) * 2020-04-17 2023-05-11 Japan As Represented By Director General Of National Institute Of Health Sciences Protein diagnostic biomarker for severe drug eruption
CN113607955A (zh) * 2020-09-16 2021-11-05 广州中医药大学顺德医院(佛山市顺德区中医院) 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用
CN113533750A (zh) * 2020-10-22 2021-10-22 广州中医药大学顺德医院(佛山市顺德区中医院) 一种区分新型冠状病毒肺炎患者与健康者的系统
KR20230036541A (ko) * 2021-09-07 2023-03-14 주식회사 에프엔씨티바이오텍 폐섬유화증의 바이오마커 및 치료 표적으로서 csf3r
WO2023081299A1 (en) * 2021-11-05 2023-05-11 Spiritus Therapeutics, Inc. A purified enriched population exosomes derived from individuals with a chronic progressive lung disease for noninvasive detection, staging, and medical monitoring of disease progression
CN114563562A (zh) * 2022-03-01 2022-05-31 复旦大学附属中山医院 Prdx6联合铁离子检测在ards进程监测中的应用
KR20240026005A (ko) * 2022-08-19 2024-02-27 울산대학교 산학협력단 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커
CN119947728A (zh) * 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
CN117025745B (zh) * 2022-11-18 2024-02-23 中国医学科学院北京协和医院 分子标志物在诊断干燥综合征中的应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
JP2005506964A (ja) * 2001-07-13 2005-03-10 バイオア ピーティーワイ リミテッド 疾患を治療するための組成物および方法
JP2008509410A (ja) * 2004-08-12 2008-03-27 エフ．ホフマン−ラ ロシュ アーゲー 肝線維症の診断方法
JP2008532493A (ja) * 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
JP2008545651A (ja) * 2005-05-17 2008-12-18 インターザー コーポレーション トール様受容体に関連する自己免疫疾患及び炎症性疾患の治療のための方法及び組成物
JP2009195233A (ja) * 2001-04-24 2009-09-03 Bayer Corp ヒトｔｉｍｐ−１抗体
WO2011054893A2 (en) * 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
US20110212473A1 (en) * 2008-10-21 2011-09-01 Jan Johannes Enghild Mmp activation peptide detection in biological samples
US20110250589A1 (en) * 2010-01-21 2011-10-13 The Regents Of The University Of Michigan Biomarkers for lung disease monitoring
US20110280865A1 (en) * 2009-01-16 2011-11-17 The Ohio State University Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof
US20120035067A1 (en) * 2008-09-05 2012-02-09 Naftali Kaminski Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation
JP2013502435A (ja) * 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． 線維性肺疾患の処置のための方法および組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6019988A (en) * 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
EP1757940A1 (en) * 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
US8709731B2 (en) * 2007-08-24 2014-04-29 Oncotherapy Science, Inc. DKK1 oncogene as therapeutic target for cancer and a diagnosing marker
WO2010102167A1 (en) * 2009-03-05 2010-09-10 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
MX2011009810A (es) * 2009-03-27 2011-09-30 Zymogenetics Inc Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
KR20140064971A (ko) * 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
CA2901384A1 (en) 2013-03-15 2014-09-18 Intermune, Inc. Proteomic ipf markers

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009195233A (ja) * 2001-04-24 2009-09-03 Bayer Corp ヒトｔｉｍｐ−１抗体
JP2005506964A (ja) * 2001-07-13 2005-03-10 バイオア ピーティーワイ リミテッド 疾患を治療するための組成物および方法
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
JP2008509410A (ja) * 2004-08-12 2008-03-27 エフ．ホフマン−ラ ロシュ アーゲー 肝線維症の診断方法
JP2008532493A (ja) * 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
JP2008545651A (ja) * 2005-05-17 2008-12-18 インターザー コーポレーション トール様受容体に関連する自己免疫疾患及び炎症性疾患の治療のための方法及び組成物
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
US20120035067A1 (en) * 2008-09-05 2012-02-09 Naftali Kaminski Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation
US20110212473A1 (en) * 2008-10-21 2011-09-01 Jan Johannes Enghild Mmp activation peptide detection in biological samples
US20110280865A1 (en) * 2009-01-16 2011-11-17 The Ohio State University Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof
JP2013502435A (ja) * 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． 線維性肺疾患の処置のための方法および組成物
WO2011054893A2 (en) * 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
US20110250589A1 (en) * 2010-01-21 2011-10-13 The Regents Of The University Of Michigan Biomarkers for lung disease monitoring

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IVAN O. ROSAS, ET AL.: "MMP1 and MMP7 as Ptential Peripheral Blood biomarkers in Idiopathic Pulmonary Fibrosis", PLOS MEDICINE, vol. Volume 5, Issue 4, JPN6017049286, April 2008 (2008-04-01), pages 0623 - 0633, ISSN: 0003913655 *
KAZUHISA KONISHI: "Gene Expression Profiles of Acute Exacerbations of Idiopathic Pulmonary Fibrosis", AM J RESPIR CRIT CARE MED, vol. 180, JPN6016046550, 16 April 2009 (2009-04-16), pages 167 - 175, ISSN: 0003913653 *
MOISES SELMAN, ET AL.: "TIMP-1,-2,-3,and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironm", AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 279, JPN6017049284, 2000, ISSN: 0003913654 *
S. MCKEOWN: "MMP expression and abnormal lung permeability are important determinants of outcome in IPF", EUR RESPIR J, vol. 33, JPN6016046551, 2009, pages 77 - 84, ISSN: 0003913652 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020090683A1 (ja) * 2018-10-29 2020-05-07 国立大学法人東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
JPWO2020090683A1 (ja) * 2018-10-29 2021-09-24 国立大学法人 東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
JP7440042B2 (ja) 2018-10-29 2024-02-28 国立大学法人 東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
JPWO2021024856A1 (enExample) * 2019-08-02 2021-02-11
WO2021024856A1 (ja) * 2019-08-02 2021-02-11 国立医薬品食品衛生研究所長が代表する日本国 間質性肺炎のタンパク質診断バイオマーカー
JP7614477B2 (ja) 2019-08-02 2025-01-16 国立医薬品食品衛生研究所長 間質性肺炎のタンパク質診断バイオマーカー

Also Published As

Publication number Publication date
CN105122068A (zh) 2015-12-02
EP2972392A1 (en) 2016-01-20
CA2901384A1 (en) 2014-09-18
MX2015012778A (es) 2016-01-20
BR112015023699A2 (pt) 2017-07-18
EP2972392A4 (en) 2017-03-22
WO2014144821A1 (en) 2014-09-18
RU2015144149A (ru) 2017-04-21
HK1219533A1 (zh) 2017-04-07
KR20150130408A (ko) 2015-11-23
US9726677B2 (en) 2017-08-08
US20140286929A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
JP2016519763A (ja) プロテオームｉｐｆマーカー
US9200322B2 (en) Biomarkers for acute ischemic stroke
JP2017518514A (ja) Ｌｐａ関連タンパク質及びｒｎａ発現
EP2834638B1 (en) Methods for diagnosis and prognosis of sepsis
Patel et al. Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning
CN107003320B (zh) 慢性肾脏疾病的快速进展的生物标志物
RU2764766C2 (ru) Гистоны и/или proadm в качестве маркеров, свидетельствующих об органной дисфункции
CN111602057B (zh) 使用降钙素原和中区肾上腺髓质素原的风险评估和患者管理的工作流程
EP3639860B1 (en) Reducing the risk of major adverse cardiac events
JP2022521390A (ja) 術後有害事象の診断または予後
JP2021508046A (ja) ｐｒｏ−ＡＤＭに基づく抗生物質療法の指導
US20240110927A1 (en) End stage renal disease biomarker panel
JP2019508395A (ja) 炎症性腸疾患の処置を改善するための腸管バリア機能の評価
JP2012526543A5 (enExample)
WO2024023139A1 (en) Methods for prognosis and monitoring pulmonary hypertension
JP2021508045A (ja) 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス
AU2022255565A1 (en) Methods of diagnosing and predicting renal decline
CN117529664A (zh) 用于预测脓毒症和脓毒性休克的方法
JP2023528069A (ja) コロナウイルス感染症罹患対象の重症度又は合併症のマーカーとしての可溶性ｔｒｅｍ－１
Maier et al. Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
Wang et al. Hydronephrosis-Associated Renal Fibrosis: Clinical Validation of Spp1 as a Biomarker and Therapeutic Target
Nicol Diagnostic and prognostic value of current phenotyping methods and novel molecular markers in idiopathic pulmonary fibrosis
RU2775090C2 (ru) Проадреномедуллин в качестве маркера, указывающего на неблагоприятное событие
CN117441104A (zh) 诊断和预测肾功能下降的方法
Gülmez et al. Urinary Peptidomic Profiling In Post‐Acute Sequelae of SARS‐CoV‐2 Infection: A Case‐Control Study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190709